Latest Aliskiren Stories

d’Oliveira & Associates has issued a new infographic providing information on a Tekturna medical study that was stopped due to patients suffering from nonfatal stroke, hyperkalemia, and hypotension. (PRWEB) April 18, 2013 Tekturna (aliskiren), produced by Novartis, is a once-daily pill used to treat high blood pressure (hypertension) and is the first “Renin Inhibitor” drug that regulates the renin enzyme in the kidney. This process assists by narrowing the blood vessels and...

Studies investigate the potential of several drugs for the treatment of patients with diabetes or kidney disease Three late-breaking studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on drugs being tested in patients with diabetes or kidney disease. Hans-Henrik Parving, MD (University of Copenhagen, in Denmark) and his colleagues investigated whether the drug aliskiren might improve the prognosis of patients with type 2 diabetes who...

Nearly 5 percent of pregnant women are prescribed drugs to treat high blood pressure, including some drugs that aren't considered safe for mothers or their babies, according to new research in the American Heart Association's journal Hypertension. Use of high blood pressure drugs during pregnancy is becoming increasingly common, said Brian T. Bateman, M.D., lead author and Assistant Professor of anesthesia at Harvard Medical School in Boston, Mass. "While we know high blood pressure, or...

Drug manufacturer deviates from the appropriate comparator therapy specified by the G-BA The fixed drug combination of aliskiren and amlodipine (trade name: Rasilamlo®) was approved in April 2011 for the treatment of people with hypertension in whom aliskiren or amlodipine alone has an insufficient effect. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG)...

Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications. The pharmaceutical company Novartis terminated a large, international clinical trial of the drug last month after finding an increased incidence after 18-24 months of non-fatal strokes, renal complications, high levels of potassium in the blood and low blood pressure. As a result,...

Women with high blood pressure (hypertension) during early pregnancy are more likely to have babies born with major birth defects, regardless of their use of prescribed medications to control the condition, according to new research published in the online edition of the British Medical Journal on Oct. 18. Pregnant women have been warned for years to avoid angiotensin-converting enzyme (ACE) inhibitors during the later stages of pregnancy to avoid the possibility of birth defects. But...

(Ivanhoe Newswire) -- Patients with high blood pressure who are given combined drug therapy from the start of treatment respond better than patients given single-drug treatment (monotherapy), according to a new study. Additionally, those who later switch from single-drug treatments to combination therapy improve their response, but not to the same level as those who began with combination therapy.All patients in the study had high systolic blood pressure. The researchers compared the drugs...

EAST HANOVER, N.J., Dec. 22, 2010 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ). The FDA approval was based on data from a double-blind, active...

A trio of studies published in the American Journal of Hypertension offers new insight into the field of personalized medicine, challenging conventional approaches to treating the hypertension suffered by one-in-three U.S. adults.The studies show that some drug combinations work better than others among certain populations.  This raises the possibility that measuring blood levels of renin, a hormone secreted by the kidneys, might help optimize the treatment of hypertension in some...

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- The US Food and Drug Administration (FDA) approved Tekamlo(TM) (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for...